Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Operating Expenses (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Operating Expenses readings, the most recent being $142.7 million for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 20.03% to $142.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $528.5 million, a 17.32% increase, with the full-year FY2025 number at $528.5 million, up 17.32% from a year prior.
  • Operating Expenses hit $142.7 million in Q4 2025 for Amicus Therapeutics, up from $115.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $148.9 million in Q2 2025 to a low of $100.4 million in Q2 2024.
  • Median Operating Expenses over the past 5 years was $116.1 million (2023), compared with a mean of $119.9 million.
  • Biggest five-year swings in Operating Expenses: dropped 21.7% in 2023 and later soared 48.29% in 2025.
  • Amicus Therapeutics' Operating Expenses stood at $146.4 million in 2021, then dropped by 17.35% to $121.0 million in 2022, then fell by 11.23% to $107.4 million in 2023, then rose by 10.66% to $118.9 million in 2024, then increased by 20.03% to $142.7 million in 2025.
  • The last three reported values for Operating Expenses were $142.7 million (Q4 2025), $115.3 million (Q3 2025), and $148.9 million (Q2 2025) per Business Quant data.